Original Article

The Effects of Exendine-4 on Insulin Producing Cell Differentiation from Rat Bone Marrow-Derived Mesenchymal Stem Cells

Fereshteh Nejad-Dehbashi, M.Sc.1, Mahmoud Hashemitabar, Ph.D.1, Mahmoud Orazizadeh, Ph.D.1,2, Somaieh Bahramzadeh, M.Sc.1, Elham Shahhosseini Pourshoushtary, M.Sc.1, Layasadat Khorsandi, Ph.D.1,*

1. Cell and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2. Department of Anatomical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

*Corresponding Addresses: P.O. Box: 61335, Cell and Molecular Research Center
Faculty of Medicine Ahvaz Jundishapur University of Medical Sciences Ahvaz, Iran
Email: layasadat@yahoo.com

Received: 1/Oct/2012, Accepted: 6/Jul/2013

Abstract

Objective: The aim of this study was to evaluate the effect of exendin-4 (EX-4) on differentiation of insulin-producing cells (IPCs) from rat bone marrow-derived mesenchymal stem cells (RAT-BM-MSCs).

Materials and Methods: In this experimental study, RAT-BM-MSCs were cultured and the cells characterized by flow cytometry analysis of cell surface markers. RAT-BM-MSCs were subsequently treated with induction media with or without EX-4. After induction, the presence of IPCs was demonstrated with dithizone (DTZ) staining and gene expression profiles for pancreatic cell differentiation markers (PDX-1, GLUT-2, insulin) were assessed using reverse transcription polymerase chain reaction (RT-PCR). Insulin excreted from differentiated cells was analyzed with radioimmunoassay (RIA). The two-tailed student's t-test was used for comparison of the obtained values.

Results: The percentage of DTZ-positive cells significantly increased in EX-4 treated cells (p<0.05). Expression of the islet-associated genes PDX-1, GLUT-2 and insulin genes in EX-4 treated cells was markedly higher than in the cells exposed to differentiation media without EX-4. RIA analysis demonstrated significant release of insulin with the glucose challenge test in EX-4 treated cells compared to EX-4 untreated cells.

Conclusion: The results of this study have demonstrated that EX-4 can enhance differentiation of IPCs from RAT-BM-MSCs.

Keywords: Exendin-4, Mesenchymal Stem Cells, Insulin-producing Cells, PDX-1, GLUT-2

Introduction

Type 1 diabetes is caused by autoimmune destruction of the pancreatic islet insulin-producing β cells. Insulin administration does not prevent long-term complications of the disease as the optimal insulin dosage is difficult to adjust. Replacement of the damaged cells with regulated insulin-producing cells (IPCs) is considered the ultimate cure for type 1 diabetes. Transplantation of intact human pancreases or isolated islets has been severely limited by the scarcity of human tissue donors and the search continues for an abundant source of human IPCs. Recent progress in stem cell biology has raised hopes for the generation of regulated IPCs by differentiation from various sources of stem/progenitor cells (1, 2).

Glucagon-like peptide 1 (GLP-1) is a 30 amino acid peptide produced in intestinal L cells and released into the bloodstream in response to food intake. It is a potent incretin, in that it increases glucose-dependent secretion of insulin by pancre-
atic β cells. It acts directly on β cells, enhancing the effect of glucose in stimulating insulin secretion from these cells. When administered to diabetic mice, GLP-1 lowers blood glucose levels and stimulates insulin secretion (3). In addition, GLP-1 increases β cell mass by inducing the differentiation and neogenesis of ductal progenitor cells into islet endocrine cells (4, 5). It has been reported that GLP-1 is capable of enhancing fetal pig β cell differentiation from progenitor epithelial cells as well as initiating their functional maturation in islet-like cell clusters (6).

GLP-1 stimulates pro-insulin gene transcription in the pancreatic β cells, decreases gastric emptying time and reduces food intake. As a result, GLP-1 has received much attention as a possible therapeutic agent in the treatment of type II diabetes and obesity. However, GLP-1 is rapidly degraded in vivo by dipeptidyl peptidase IV (DPP IV) (7).

Exendin-4 (EX-4), a 39-amino acid peptide, is a GLP-1 receptor agonist that is a more potent, longer lasting insulinotropic peptide than GLP-1. The ten-fold increase in potency of EX-4 in vivo relative to GLP-1 is attributed to: a. increased metabolic stability as the compound is resistant to cleavage by DPP IV and many of the neutral endopeptidases that degrade GLP-1, and b. its increased affinity for the GLP-1 receptor. EX-4 is being assessed in clinical trials as a potential treatment for hyperglycemia. EX-4 and GLP-1 share a 53% amino acid sequence homology. The major difference between EX-4 and GLP-1 is in the nine amino acid C terminal sequence of EX-4, which is not present in GLP-1. Recent studies of the solution nuclear magnetic resonance (NMR) structure of the peptides show that, although both GLP-1 and EX-4 exhibit a highly helical tertiary structure, EX-4 is more stable. The helical structure of EX-4 is stabilized by the compact conformation formed by amino acids 27–39 that form a hydrophobic Trp-cage fold feature that caps and stabilizes the helix (8).

It has been previously reported that EX-4 is capable of stimulating both the differentiation of β cells from ductal progenitor cells and proliferation of β cells when administered to rats and humans (9-11).

In the present study we examined the possibility that EX-4 could enhance the differentiation of IPCs from rat bone marrow-derived mesenchymal stem cells (RAT-BM-MSCs).

Materials and Methods

**Isolation of rat bone marrow mesenchymal stem cells**

This study was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences. RAT-BM-MSC cultures were prepared under sterile conditions (9). Briefly, the femur and tibia of the rats were excised with special attention given to the removal of all connective tissue attached to the bones. Bone marrow was extruded from these bones by flushing the bone marrow cavity by syringe with an attached 20-gauge needle. The syringe was filled with culture medium (DMEM) supplemented with 10% fetal calf serum (FCS). The harvested RAT-BM-MSCs were gently pipetted to break up cell clumps in order to obtain a cell suspension. After a homogenous cell suspension was achieved, the cells were centrifuged at 1200 rpm for 7 minutes and the cell pellet was resuspended in 3 ml of culture medium. The cell suspension was seeded in 25 cm² plastic tissue culture flasks with 5 ml culture medium and maintained at 37°C in a humidified atmosphere with 5% CO₂. Cultures of RAT-BM-MSCs were inspected and refed every three days and passaged when the RAT-BM-MSCs reached approximately 80% confluency. The mesenchymal population was isolated on the basis of its ability to adhere to the culture plate (12-14).

**Flow cytometry analysis**

We used flow cytometry to determine expression of cell surface markers on the RAT-BM-MSCs culture prior to the use of differentiation media. Flow cytometry was performed in Department of Immunology of Ahvaz Jundishapur University of Medical Sciences. The cells were characterized with regard to a set of markers characteristic for RAT-BM-MSCs that included CD44, CD105, CD45, and CD34 (15).

**Induction of rat bone marrow mesenchymal stem cells to IPCs**

For induction, passage-3 bone marrow-derived RAT-BM-MSCs were divided into the follow-
ing groups. Group 1 was cultured in DMEM, group 2 was cultured in IPC differentiation media and we cultured group 3 in IPC differentiation media plus EX-4 (Sigma, Germany). A three-stage protocol was used to induce IPC, as follows. For stage 1, the cells (1×10^5/ml were cultured at 37˚C and 5% CO_2 for two days in serum-free high glucose DMEM (25 mmol/L) that contained 0.5 mmol/L β-mercaptoethanol (Invitrogen, USA). In stage 2 the cells were subsequently cultured in medium that contained 1% non-essential amino acids (Invitrogen, USA), 20 ng/ml fibroblast growth factor (FGF, Sigma-Aldrich), 20 ng/ml EGF (Sigma-Aldrich), 2% B27 (Invitrogen), and 2 mmol/L L-glutamine (Hyclone Laboratories, Inc., USA) in six-well plates for eight days. For stage 3, we cultured the cells for an additional eight days in new medium that contained 10 ng/ml β-cellulin (Sigma-Aldrich), 10 ng/ml activin A (Sigma-Aldrich), 2% B27 and 10 mmol/L nicotinamide (Sigma-Aldrich) (16). In the EX-4 group, 10 ng/ml EX-4 was added to the differentiation medium in stages 2 and 3.

Dithizone staining

Ten mg Dithizone (Sigma-Aldrich) was completely dissolved in 10 ml of dimethyl sulfoxide (DMSO, Sigma-Aldrich, USA) and was stored at -20˚C. The working solution (pH=7.8) was prepared immediately prior to use by diluting the stock solution (1:10) in PBS. For each dish, 2 ml of the DTZ solution were added and allowed to incubate for 30 minutes at 37˚C. Average percentages of cells that stained with DTZ were calculated by dividing the number of DTZ positive cells in a random microscopic field by the total number of cells in the same field, after which the result was multiplied by 100. For each culture the mean of three fields was considered (17, 18).

RNA preparation and reverse transcription polymerase chain reaction

Using the RNeasy Mini Kit Qiagen, Valencia, CA, USA), RNA was isolated from the harvest cells according to the manufacturer’s instructions. Reverse transcription polymerase chain reaction (RT-PCR) was performed using a One-Step RT-PCR Kit (Qiagen, Valencia, CA, USA) which contains reverse transcriptase to synthesise cDNA from the isolated RNA and DNA polymerase for the PCR. RT-PCR conditions consisted of a 30 minute step at 50˚C to allow for reverse transcriptase activity followed by 15 minutes at 95˚C to deactivate the reverse transcriptase and activate Taq polymerase present in the enzyme mixture. The PCR process consisted of 6 seconds at 94˚C (denaturing step), 30 seconds at the annealing temperature (55˚C), and a 45 second step at 72˚C for extension with all steps repeated for 30 cycles. A final extension step lasted 10 minutes at 72˚C.

Primer sequences were as follows with the expected product length: PDX-1, sense 5’ AAACGCCACACACAAAGGAGAA 3’ and antisense 5’ AGACCTGGCGGTTCACATG 3’ (150 bp); GLUT-2, sense 5’ CAGCTGTCTCTGTGCTGCTTGT 3’ and antisense 5’ GCCGTCACTGCTCACATACTCA 3’ (150 bp); insulin, sense 5’ TCTTCTACACACCCGACGTTCGGCACACCTGCTCCC 3’ and antisense 5’ GGTGCGAGCAGCATCCTAGAC 3’, (149 bp). GAPDH, sense 5’ TCTGCTGACCTGCCATGATCCAC 3’, (105 bp), was used as the housekeeping gene (19).

Radioimmunoassay

The differentiated cells were pre-incubated for one hour in glucose-free Krebs-ringer bicarbonate (KRB) and incubated with KRB that contained 5.56 mmol/L, 16.7 mmol/L or 25 mmol/L of glucose (glucose challenge) for an additional one hour, respectively. The KRB media were collected and frozen at -80˚C until assayed (20). The insulin assay was performed by radioimmunoassay (RIA) using a commercially available rat RIA kit (Millipore) according to the manufacturer’s instructions. Determinations were carried out in triplicate and the means and standard deviations were obtained.

Statistical analysis

A two-tailed student’s t test was used for comparing the obtained values. For statistical purposes at least three independent cultures were considered. All values have been stated as means ± standard deviations. P<0.05 was considered to be statistically significant.
Results

Cell surface markers detected by flow cytometry revealed that RAT-BM-MSCs highly expressed CD105 and CD44, whereas there were no expressions of CD34 and CD45 detected (Fig 1).

Morphological changes of rat bone marrow mesenchymal stem cell differentiation

Under an inverted microscope, undifferentiated RAT-BM-MSCs were typical of adherent spindle and fibrocyte-like cells at passage 3 (Fig 2). The RAT-BM-MSCs cultured in undifferentiation media (control group) showed various shapes including spherical, neuron-like cells or glial-like cells (Fig 3A). Under differentiation media with EX-4, the RAT-BM-MSCs forming spherical type with confluence similar to pancreatic islet-like cells. Round shape morphology in differentiation media without EX-4 were lesser than those exposed to differentiation media containing EX-4 (Fig 3B, C).
**Dithizone staining**

To verify the insulin expression in the differentiated cells, dithizone which specifically stains insulin granules present in β-cell was used. As shown in Figure 4, most of the cells in IPC differentiation media were positive for dithizone staining, especially in presence of EX-4. The percentage of dithizone positive cells were significantly increased in group IPC differentiation media without EX-4 (group 1) and with EX-4 (group 2) compared to control group. The percentage of stained cells (Fig 5) in group 2 were significantly higher than group 1 ($p<0.05$).

**Gene expression of bone marrow-derived IPCs**

To determine whether RAT-BM-MSCs had undergone pancreatic differentiation, we assessed gene expression profiles for pancreatic cell differentiation markers by RT-PCR. As illustrated in Figure 6, low expression levels of PDX-1, GLUT-2 and insulin was detected in undifferentiated RAT-BM-MSCs (control). In RAT-BM-MSCs treated by differentiation media without EX-4 (group 1), expression of these genes was markedly higher in compare to control. In EX-4 treated cells expression of these genes were higher than group 1.

![Fig 4: DTZ staining of RAT-BM-MSCs. A. Spontaneously differentiated rat bone marrow mesenchymal stem cells (RAT-BM-MSCs) in DMEM stained positive for dithizone (DTZ). B. DTZ-positive cells in insulin-producing cell (IPC) differentiation media without exendin-4 (EX-4). C. DTZ-positive RAT-BM-MSCs in IPC differentiation media with EX-4. Magnification: ×400.](image)

![Fig 5: Percentage of dithizone (DTZ) staining in various groups. Values are expressed as mean ± SD. *: $p<0.01$, **: $p<0.001$, ζ: $p<0.001$, * and ζ: Compared to control and group 1, respectively.](image)

![Fig 6: Expression of genes encoded in β cell markers of various groups.](image)
**Insulin release in response to glucose stimulation**

Cultured RAT-BM-MSCs in the control group showed no significant release of insulin in the presence or absence of the glucose challenge. The differentiated cells in the absence of EX-4 released insulin at a low concentration of glucose (5.56 mmol/L) and released approximately 2.5 fold insulin under glucose challenge (25 mmol/L; p<0.01). There was significantly more insulin secretion of differentiated cells in the presence of EX-4 at a low concentration of glucose and under glucose challenge compared to untreated EX-4 cells (p<0.01). The results of RIA are depicted in figure 7.

![Graph showing insulin excretion changes in various groups](image)

**Fig 7: Insulin excretion changes in various groups. Values are expressed as mean ± SD. *; p<0.001, †; p<0.001, * and †: Compared to control and group 1, respectively.**

**Discussion**

Transplantation of pancreatic islet cells and utilization of stem cells as a potential cure for diabetes mellitus have become the subjects of intense interest and activity over the past several years (21-23). However, some obstacles, such as limited supply of human islet tissue, immune rejection, and ethical issues remain. Bone marrow has been known for years as a safe, abundant source for large quantities of adult stem cells (24). In the present study we have demonstrated that EX-4 affected the transdifferentiation process of RAT-BM-MSCs cells to IPCs. Park et al. (25) showed that EX-4 and exercise promoted β cell function and mass in islets of diabetic rats. Stoffers et al. (26) reported that exposure to EX-4 in the newborn period reversed the adverse consequences of fetal programming and prevented the development of diabetes in adulthood. It has been revealed that GLP-1 promotes the expansion of pancreatic β cell mass by stimulating neogenesis as well as proliferation of existing β cells (27-29). Administration of the long-acting GLP-1 analog EX-4 during regeneration after 90% partial pancreatectomy in rats has resulted in a sustained improvement in glucose homeostasis associated with a 40% increase in β cell mass due to increases in both neogenesis and replication (3). Further, chronic treatment of adult diabetic mice with either GLP-1 or EX-4 also improves glucose tolerance, increases islet size, and stimulates pancreatic duodenal homeobox (PDX) protein expression in the pancreas (10).

In this study the existence of IPCs was confirmed by DTZ staining and expression pattern analysis of islet-specific genes. We have shown that expression of PDX-1 in EX-4 treated cells markedly increased. PDX is a pancreatic homeoprotein critical for early development of both the endocrine and exocrine pancreas. It mediates glucose-responsive stimulation of insulin gene transcription (30). PDX-1 plays a crucial role in the control of several genes expressed in the pancreas. Its capacity to activate gene transcription in a tissue specific mode is dependent on its ability to interact with other transcription factors (31, 32).

**PDX-1 binds and transactivates the promoters of several physiologically relevant genes within the β cell, including insulin, glucose transporter 2 (GLUT-2), glucokinase, and islet amyloid polypeptide (33). There were elevated expressions of insulin 2 and GLUT-2 genes in EX-4 treated cells in the present study. It has been reported that expressions of these genes indicate differentiation and fully functional IPCs. Additionally, RIA analysis has demonstrated significant expression of insulin upon glucose challenge in EX-4 treated cells compared to untreated cells.**

In pancreatic β cells, glucose uptake is controlled by GLUT-2, which is essential in the mechanism of glucose-induced insulin secretion (34). GLUT-2 is the glucose sensor of β cells that leads to the production of insulin (35). GLP-1 increases insulin secretion and the biosynthesis of important β cell
products in addition to insulin such as glucokinase and GLUT-2 glucose transporters (36). The present study has also detected insulin gene expression in non-induced cells (control), which indicated that RAT-BM-MSCs could spontaneously differentiate into IPCs. This result supported previous findings that adult stem cells could spontaneously differentiate (37).

Conclusion

This study has demonstrated that EX-4 can enhance the differentiation of RAT-BM-MSCs into insulin producing cells. However, further studies are needed to understand the mechanism of action of EX-4 on MSCs.

Acknowledgments

The financial cost of this project was provided by the Research Council of Ahvaz Jundishapur University of Medical Sciences (Grant number: CM-004). There is no conflict of interest in this article.

References

1. Zalzman M, Anker-Kitai L, Efrat S. Differentiation of human liver-derived, insulin-producing cells toward the beta-cell phenotype. Diabetes. 2005; 54(9): 2568-2575.
2. Saeinasab M, Moghaddam-Matin M, Bahrami AR. In vitro differentiation of blastema cells derived from new zealand white rabbit pinna into insulin producing cells. Cell J. 2010; 12 Suppl 1: Ps-46.
3. Xu G, Stoffers DA, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999; 48(12): 2270-2276.
4. Hui L, Wright C, Perfetti R. Glucagon-like peptide 1 induces differentiation of islet duodenal hormone-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes. 2001: 50(4): 785-796.
5. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology. 2002; 143(8): 3152-3161.
6. Hardikar AA, Wang XY, Williams LJ, Kwok J, Wong R, Yao M, et al. Functional maturation of fetal porcine beta-cells by glucagon-like peptide 1 and cholecystokinin. Endocrinology. 2002; 143(9): 3505-3514.
7. López de Maturana R, Willshaw A, Kuntzsch A, Rudolph R, Donnelly D. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1. J Biol Chem. 2003; 278(12): 10195-10200.
8. Doyle ME, McConville P, Theodorakis MJ, Goetschkes MM, Bernier M, Spencer RG, et al. In vivo biological activity of exendin (1-30). Endocrine. 2005; 27(1): 1-9.
9. Zhou J, Wang X, Pineyro MA, Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes. 1999; 48(12): 2358-2366.
10. Stoffers DA, Kieffer T, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes. 2000; 49(5): 741-748.
11. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord. 2003; 27(3): 313-318.
12. Moradi F, Haji Ghasedar M, Gholian MT, Lashkarboulaki T. Spontaneous expression of neurotrophic factors and TH, Nurr1, Nestin genes in long-term culture of bone marrow mesenchymal stem cells. Cell J. 2012; 13(4): 243-250.
13. Wakitani S, Saito T, Caplan Al. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve. 1995; 18(12): 1417-1426.
14. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 2003; 108(7): 863-868.
15. Karaoz E, Aksoy A, Ayhan S, Sanboycaci AE, Kayma M. Characterization of mesenchymal stem cells from rat bone marrow: ultrastructural properties, differentiation potential and immunophenotypic markers. Histocommun Cell Biol. 2009; 132(5): 533-546.
16. Sun Y, Chen L, Hou XG, Hou WK, Dong JJ, Sun L, et al. Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro. Chin Med J (Engl). 2007; 120(9): 771-776.
17. Shiroi A, Yoshikawa M, Yokota H, Fukuji H, Ishizaka S, Tatsumi K, et al. Identification of insulin-producing cells derived from embryonic stem cells by zinc-chelating dithizone. Stem Cells. 2002; 20(4): 284-292.
18. Koblas T, Leonovčík M, Zacharová K, Berková Z, Kříž J, Girman P, et al. Activation of the Jak/Stat signalling pathway by leukaemia inhibitory factor stimulates trans-differentiation of human non-endocrine pancreatic cells into insulin-producing cells. Folia Biol (Praha). 2012; 58(3): 98-105.
19. Sun Y, Zhang L, Gu HF, Han W, Ren M, Wang F, et al. Peroxisome proliferator-activated receptor-1 regulates the expression of pancreatic/duodenal homebox-1 in rat Insulinoma (INS-1) cells and ameliorates glucose-insulin secretion impaired by palmitate. Endocrinology. 2007; 149(2): 662-671.
20. Gabr MM, Ismail AM, Refaie AF, Ghoneim MA. Differentiation of rat bone marrow-derived mesenchymal stem cells into insulin-producing cells. J Basic Appl Sci Res. 2011; 1(5): 398-404.
21. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000; 343(4): 230-238.
22. Otonkoski T, Gao R, Lundin K. Stem cell in the treatment of diabetes. Ann Med. 2005; 37(7): 513-520.
23. Burns CJ, Persaud SJ, Jones PM. Stem cell therapy for diabetes: Do we need to make beta cells? J Endocrinol. 2004; 183(3): 437-443.
24. Hesch D, Li L, Martin M, Sakano S, Hill D, Strutt B, et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotechnol. 2003; 21(7): 763-770.
25. Park S, Hong SM, Sung SR. Exendin-4 and exercise promotes beta-cell function and mass through IRS2 induction.
EX-4 Enhance IPC Differentiation from RAT-BM-MSCs

26. Stoffers DA, Desai BM, DeLeon DD, Simmons RA. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes. 2003; 52(3): 734-740.

27. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia. 2002; 45(9): 1263-1273.

28. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab. 2002; 283(4): E745-752.

29. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes. 2002; 51(5): 1443-1452.

30. Edlund H. Transcribing pancreas. Diabetes. 1998; 47(12): 1817-1823.

31. Ashizawa S, Brunicardi FC, Wang XP. PDX-1 and the pancreas. Pancreas. 2004; 28(2): 109-120.

32. Khodadadi L, Jafari H, Farrokhi A, Pirouz M, Baharvand H. From pancreatic development to mellitus diabetes treatment. Yakhteh. 2006; 8(2): 70-161.

33. Peshavaria M, Cissell MA, Henderson E, Petersen HV, Stein R. The PDX-1 activation domain provides specific functions necessary for transcriptional stimulation in pancreatic beta-cells. Mol Endocrinol. 2000; 14(12): 1907-1917.

34. Olson AL, Pessin JE. Structure function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr. 1996; 16: 235-256.

35. Lopes Da Costa C, Sampaio De Freitas M, Sanchez Moura A. Insulin secretion and GLUT-2 expression in undernourished neonate rats. J Nutr Biochem. 2004; 15(4): 236-241.

36. Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009; 124(1): 113-138.

37. Deng J, Petersen BE, Steindler DA, Jorgensen ML, Laywell ED. Mesenchymal stem cells spontaneously express neural proteins in culture and are neurogenic after transplantation. Stem Cells. 2006; 24(4): 1054-1064.